Screening of 22q11.2DS using multiplex ligation-dependent probe amplification as an alternative diagnostic method

Sathiya Maran, Siti Aisyah Faten, Swee Hua Erin Lim, Kok Song Lai, Wan Pauzi Wan Ibrahim, Ravindran Ankathil, Siew Hua Gan, Huay Lin Tan, Nicola Ielapi

    Research output: Contribution to journalArticleResearchpeer-review


    Background. The 22q11.2 deletion syndrome (22q11.2DS) is the most common form of deletion disorder in humans. Low copy repeats flanking the 22q11.2 region confers a substrate for nonallelic homologous recombination (NAHR) events leading to rearrangements which have been reported to be associated with highly variable and expansive phenotypes. The 22q11.2DS is reported as the most common genetic cause of congenital heart defects (CHDs). Methods. A total of 42 patients with congenital heart defects, as confirmed by echocardiography, were recruited. Genetic molecular analysis using a fluorescence in situ hybridization (FISH) technique was conducted as part of routine 22q11.2DS screening, followed by multiplex ligation-dependent probe amplification (MLPA), which serves as a confirmatory test. Results. Two of the 42 CHD cases (4.76%) indicated the presence of 22q11.2DS, and interestingly, both cases have conotruncal heart defects. In terms of concordance of techniques used, MLPA is superior since it can detect deletions within the 22q11.2 locus and outside of the typically deleted region (TDR) as well as duplications. Conclusion. The incidence of 22q11.2DS among patients with CHD in the east coast of Malaysia is 0.047. MLPA is a scalable and affordable alternative molecular diagnostic method in the screening of 22q11.2DS and can be routinely applied for the diagnosis of deletion syndromes.

    Original languageEnglish
    Article number6945730
    Number of pages6
    JournalBioMed Research International
    Publication statusPublished - 28 Sep 2020

    Cite this